What Is ESMO? The ESMO Conference, ESMO Asia 2026 Singapore and Better Cancer Care

What Is ESMO? The ESMO Conference, ESMO Asia 2026 Singapore and Better Cancer Care

The treatment a cancer patient receives next year may first have been debated in a congress hall this year. That is the quiet power of ESMO and the ESMO conference: they turn new evidence into shared standards that oncologists everywhere can use.

If you are a clinician, researcher or medical affairs professional, you have probably sat in one of its sessions. Here is what ESMO actually is, how its work reaches patients, and why ESMO Asia 2026 in Singapore, one of the key ESMO 2026 meetings, is worth your time.

What is ESMO? The society behind the ESMO conference

ESMO, the European Society for Medical Oncology, is a leading professional organisation for medical oncology. Founded in 1975 and based in Lugano, Switzerland, it represents more than 50,000 oncology professionals worldwide.

Despite the "European" in its name, its reach is global. Its work falls into a few big areas:

  • Congresses: the flagship ESMO Congress each year, the ESMO conference most oncologists know, plus regional and specialist meetings such as ESMO Asia in Singapore.
  • Clinical guidelines: evidence-based recommendations on how to diagnose, treat and follow up different cancers.
  • Education: training and resources for oncologists at every stage of their career.
  • Policy: advocating for equal access to effective cancer care, wherever a patient lives.

How ESMO is changing lives for the better

Most patients will never hear the name ESMO. Yet its work shapes the decisions made in their consultation rooms. Here is how.

1. New evidence reaches clinics faster

Practice-changing trial results are often presented first at an ESMO conference. Thousands of oncologists hear them at the same moment, discuss them in the hallway, and take them back to their own patients.

2. Shared standards of care

ESMO's clinical practice guidelines translate a flood of studies into clear recommendations. A patient in Singapore, Mumbai or Madrid is more likely to be offered a treatment backed by the best available evidence.

3. An honest measure of benefit

In 2015, ESMO introduced the Magnitude of Clinical Benefit Scale (ESMO-MCBS). It grades how much meaningful benefit a cancer medicine actually delivers, cutting through hype about "breakthroughs".

The World Health Organization's expert committee uses the scale as a screening tool when choosing cancer medicines for its Essential Medicines List. That list guides which drugs countries prioritise, so this work affects access to treatment far beyond Europe.

4. Care that fits Asia

Through its Pan-Asian Guidelines Adaptation (PAGA), ESMO works with oncology societies across Asia to adapt its guidelines to the region's patients, drug access and health systems. A standard is only useful if it can be applied where the patient is.

ESMO Asia 2026 in Singapore: dates, venue and what to expect

ESMO Asia 2026 takes place from 4 to 6 December at the Suntec Singapore Convention & Exhibition Centre. It brings together oncology professionals from across the Asia-Pacific region and beyond.

The programme focuses on the cancers most common in Asia, with sessions on biomarker-driven and targeted therapies, molecular oncology, rare cancers, artificial intelligence and access to treatment across diverse health systems. The Pan-Asian guideline sessions are a central feature.

For anyone treating patients in the region, ESMO Singapore is three days of the most relevant evidence, all in one place.

After ESMO: turning new evidence into content, fast

An ESMO conference only changes care if the new evidence reaches the people who need it. For medical affairs and marketing teams, that means turning fresh trial readouts and publications into slide decks, KOL presentations and education, quickly and accurately. Every claim has to survive medical, legal and regulatory (MLR) review.

That is what Bionidi is built for. It is an AI platform that turns approved scientific evidence into finished medical content: MOA and KOL decks, explainer videos, infographics, e-detailers and e-learning.

  • Evidence-mapped: every claim is linked to its source, with an MLR evidence report generated as the content is created.
  • Human in control: your team approves the content brief before anything is produced.
  • On brand: colours, fonts and voice follow your brand guidelines.
  • Secure: your data is not used to train models.

So the data you hear at ESMO Asia on Friday can become review-ready content your field teams can use, without weeks of agency back-and-forth.

We're attending ESMO Asia 2026 in Singapore. Let's meet.

The Bionidi team will be at ESMO Asia 2026 in Singapore from 4 to 6 December.

We would love to meet medical affairs, scientific communications and brand teams at ESMO Singapore, to hear how you turn congress data into content today and to show you what Bionidi can do.

Meet us in Singapore, or write to us at [email protected].

Bionidi is independent and not affiliated with ESMO.